Twelve, Inc. is transforming mitral valve replacement.
Oculeve is developing a novel treatment for Dry Eye, a disease affecting many millions of people worldwide.
St. Francis Medical offers a surgical implant for the treatment of spinal stenosis, a common cause of back pain, particularly in older patients. Kyphon acquired St. Francis for a total of $725 million December 2006, and is now part of Medtronic.
Lutonix is developing a drug-eluting balloon for the treatment of peripheral vascular and coronary restenois. C.R. Bard acquired Lutonix for about $225 million December 2011. Read More
LipoSonix is developing a medical device to noninvasively and permanently remove unwanted fat from the body. Medicis acquired LipoSonix for at least $150 million July 2008.
LenSx Lasers is developing a next generation laser to make cataract surgery safer and more effective. Alcon acquired LenSx for at least $361.5 million July 2010.
IntraLase develops and manufactures femtosecond lasers which create safer, more precise corneal flaps for improved laser vision correction surgery. IntraLase went public June 2004.
Insulet is commercializing a disposable insulin pump for the treatment of diabetes. Insulet went public May 2007.
ForSight NewCo II is developing an implantable drug delivery device. QLT acquired ForSight NewCo II for $42 million October 2007.
eyeonics has developed a proprietary presbyopic intraocular lens. Bausch & Lomb acquired eyeonics February 2008.
Acclarent offers a novel system for “balloon sinuplasty” to treat sinus disease. It has been reported by others that Ethicon, a Johnson & Johnson company, acquired Acclarent for approximately $785 million January 2010.
Ablation Frontiers is developing a catheter system to treat atrial fibrillation. In February 2009, it was reported by others that Medtronic acquired Ablation Frontiers for $225 million plus potential additional payments contingent upon achievement of certain clinical milestones.
WaveTec is commercializing an ophthalmic surgical guidance system. Alcon acquired WaveTec in August 2014.
Second Sight is developing a prosthetic retinal implant which will return functional vision to patients blinded from retinitis pigmentosa and age-related macular degeneration. Second Sight completed its IPO in November 2014.
Inogen develops and manufactures innovative, portable, lightweight oxygen concentrators for the home and ambulatory oxygen markets. Inogen went public in February 2014.
Glaukos is developing an implantable device to treat glaucoma.
Cameron Health is developing a novel Implantable Cardioverting Defibrillator (S-ICD) without intravenous leads. Boston Scientific acquired Cameron Health for up to $300 million March 2012 with a potential of an additional $1.050 billion upon specific achievements. Read More